parsaclisib
Small moleculeexperimental
Clinical trial activity
36 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
19
Phase 2
22
Phase 3
5
Phase 4
0
Earliest trial started Aug 1, 2014 (NCT02265510)
Timeline
Indications
Studied for
- Anemia, Hemolytic, Autoimmune · Phase 3
- Antineoplastic Combined Chemotherapy Protocols · Phase 1/Phase 2
- Breast Neoplasms · Phase 1
- Carcinoma, Renal Cell · Phase 1
- Carcinoma, Transitional Cell · Phase 1
- Colorectal Neoplasms · Phase 1
- Drug Therapy · Phase 1/Phase 2
- Endometrial Neoplasms · Phase 1
- Head and Neck Neoplasms · Phase 1
- Hodgkin Disease · Phase 2
- Leukemia, B-Cell · Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1/Phase 2
- Lung Neoplasms · Phase 1
- Lymphoma · Phase 2
- Lymphoma, B-Cell · Phase 1
- Lymphoma, B-Cell, Marginal Zone · Phase 3
- Lymphoma, Follicular · Phase 3
- Lymphoma, Large B-Cell, Diffuse · Phase 1
- Lymphoma, Large-Cell, Anaplastic · Phase 1
- Lymphoma, Mantle-Cell · Phase 3
- Lymphoma, Non-Hodgkin · Phase 2
- Lymphoma, T-Cell, Peripheral · Phase 1/Phase 2
- Melanoma · Phase 1
- Mycosis Fungoides · Phase 1
- Myeloproliferative Disorders · Phase 2
- Neoplasms · Phase 1/Phase 2
- Pancreatic Neoplasms · Phase 1
- Pemphigus · Phase 2
- Phosphatidylinositol 3-Kinases · Phase 1/Phase 2
- Polycythemia Vera · Phase 3
- Primary Myelofibrosis · Phase 3
- Sjogren's Syndrome · Phase 2
- Triple Negative Breast Neoplasms · Phase 1
Mechanism of action
PIK3C2B inhibitor
- PI3-kinase p110-delta subunitINHIBITOR
PI3-kinase p110-delta subunit inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCOc1c([C@H](C)n2nc(C)c3c(N)ncnc32)cc(Cl)c(F)c1[C@@H]1CNC(=O)C1- Mol. weight
- 432.89 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297615 ↗
Also known as
- incb050465
- incb050465
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05867030 | Phase 1 | Jul 28, 2023 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT05238064 | Phase 1/Phase 2 (Phase 2) | Mar 31, 2022 | Fudan University |
| NCT04796922 | Phase 3 | Feb 1, 2022 | Incyte |
| NCT04849715 | Phase 3 | Jan 15, 2022 | Incyte |
| NCT05083208 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2021 | Henan Medical University |
| NCT05073458 | Phase 3 | Nov 12, 2021 | Incyte |
| NCT05073250 | Phase 2 | Nov 1, 2021 | People's Liberation Army of China |
| NCT04809467 | Phase 1/Phase 2 (Phase 2) | Sep 16, 2021 | Incyte |
| NCT04774068 | Phase 1 | Sep 1, 2021 | Ohio State University |
| NCT04831996 | Phase 1 | May 4, 2021 | Incyte |
| NCT04831944 | Phase 1 | Mar 29, 2021 | Incyte |
| NCT04551053 | Phase 3 | Dec 31, 2020 | Incyte |
| NCT04661007 | Phase 1 | Dec 10, 2020 | Incyte |
| NCT04551066 | Phase 3 | Nov 30, 2020 | Incyte |
| NCT04434937 | Phase 2 | Sep 14, 2020 | Incyte |
| NCT04509700 | Phase 2 | Aug 3, 2020 | Incyte |
| NCT04323956 | Phase 1 | May 15, 2020 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT04298879 | Phase 2 | Mar 31, 2020 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT04142554 | Phase 1 | Oct 31, 2019 | Incyte, University of North Carolina at Chapel Hill |
| NCT03780166 | Phase 2 | Mar 31, 2019 | Incyte |
Showing 20 of 36 trials
Page 1 / 2
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Incyte | For profit | 29 | 28 | 3 | 2014 |
| Innovent Biologics (Suzhou) Co. Ltd. | For profit | 2 | 2 | 2 | 2020 |
| Fudan University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Henan Medical University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2020 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2020 |
| Ohio State University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| People's Liberation Army of China | Government | 1 | 1 | 1 | 2021 |
| University of North Carolina at Chapel Hill | Academic/Hospital | 1 | 1 | 1 | 2019 |
9 organizations
Page 1 / 1